Back to companies

Shenzhen Salubris Pharmaceuticals Co Ltd: Overview

Shenzhen Salubris Pharmaceuticals Co Ltd (Salubris) focuses on research, development, manufacture and distribution of pharmaceutical products. The company produces and markets medicines to treat diabetes; partial onset seizures; cardiovascular and cerebrovascular indications. It also offers anti-tumor; and anti-infective drugs targeting septicemia, meningitis, respiratory, skin and soft tissue, genital and reproductive system infections. Salubris is investigating small molecules and biologic therapeutics for the treatment of metabolic, oncology, and also bone diseases. The company is also developing interventional medical devices for use in cardiology, cerebrovascular, structural heart, and peripheral vascular disease areas through its subsidiaries. It has operations in the US, Germany, France and Japan. Salubris is headquartered in Shenzhen, China.

Headquarters China

Address F37, Main Building,Chegong Temple, Lvgem Neo Square,No.6009 Shennan Boulvrd, Futian District, Shenzhen, Guangdong, 518040


Telephone 86 755 83867888

No of Employees 3,236

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 002294 (SHE)

Revenue (2020) $474.2M 11.7% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX 776.9% (2020 vs 2019)

Market Cap* $3.8B

Net Profit Margin (2020) XXX 686.0% (2020 vs 2019)

* As of and is in US$

Access premium data and analytics for Shenzhen Salubris Pharmaceuticals Co Ltd

90+

Clinical Trials

Determine Shenzhen Salubris Pharmaceuticals Co Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

40+

Pipeline Drugs

Identify which of Shenzhen Salubris Pharmaceuticals Co Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Marketed Drugs

Understand Shenzhen Salubris Pharmaceuticals Co Ltd’s commercialized product portfolio to stay one step ahead of the market.

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Shenzhen Salubris Pharmaceuticals Co Ltd’s relevant decision makers and contact details.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

14+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

9

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

4

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

3

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Shenzhen Salubris Pharmaceuticals Co Ltd’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Pipeline
Small Molecules and Biologic Therapeutics:
Cardiovascular Diseases
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Regulatory Approval In January, the company received the notice of approval of clinical trials approved and issued by National Medical Products Administration to carry out clinical trials of Allisartan Isoproxil Amlodipine Besylate Tablets.
2018 Contracts/Agreements In June, the company agreed to acquire 100% stake in Suzhou Huanchen.
2018 Financing Agreements In January, the company invested in Sichuan Jinjiang Electronic Science and Technology Co., Ltd.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Shenzhen Salubris Pharmaceuticals Co Ltd Shanghai Pharmaceuticals Holding Co Ltd Shanghai Fosun Pharmaceutical (Group) Co Ltd Huadong Medicine Co Ltd Jiangsu Hengrui Medicine Co Ltd
Headquarters China China China China China
City Shenzhen Shanghai Shanghai Hangzhou Lianyungang
State/Province Guangdong Shanghai Shanghai Zhejiang Jiangsu
No. of Employees 3,236 47,056 36,279 12,427 24,491
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Ye Chenghai Chairman Executive Board 2007 79
Yang Jianfeng President; Director Executive Board 2010 47
Yan Jie Director; Deputy General Manager Executive Board 2018 50
Kevin Sing Ye Managing Director Senior Management 2007 48
Chen Ping Deputy General Manager Senior Management 2007 52
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer